New aromatase inhibitors for breast cancer

Drug and Therapeutics Bulletin

Volumn 35, Issue 7, 1997, Pages 55-56

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; THROMBOEMBOLISM;

EID: 0030663770     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1997.35755     Document Type: Short Survey

References (11)

1. Wiseman LR, McTavish D. Formestane: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs 1993; 45: 66-84.
2. Miller WR. The clinical relevance of aromatase activity in breast tumour tissue. In: Jonat W, Santen RJ (Eds). Aromatase inhibition: present and future. Camforth. Parthenon Publishing Group, 1991.
3. ▼ Anastrozole. Summary of product characteristics, UK. Zeneca Limited, May 1996.
4. ▼ Letrozole. Summary of product characteristics, UK. Ciba Pharmaceuticals, November 1996.
5. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543-8.
6. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77:324-31.
7. Jonat W, Howell A, Blomqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404-12.
8. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A for the Aromatase Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in post menopausal women with advanced breast carcinoma. Cancer 1997; 79: 730-9.
9. Buzdar A, Jonat W, Howell A, Yin H, Lee D on behalf of the Arimidex International Study Group. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc Am Soc Clin Oncol 1997; 16: 156a [abstract].
10. Smith I, Dombernowsky P, Falkson G et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5mg letrozole over megestrol acetate (MA). Eur J Can 1996; 32A (suppl 2): 49 [abstract].
11. Marty M, Gershanovich M, Campos B et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens Proc Am Soc Clin Oncol 1997; 16: 156a [abstract].